Results 71 to 80 of about 11,904 (210)

A 24-Week, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety and Tolerability of the Rivastigmine Patch in Japanese Patients with Alzheimer’s Disease

Dementia and Geriatric Cognitive Disorders Extra, 2011
Background: As of 2010, the rivastigmine patch was licensed for the treatment of Alzheimer’s disease (AD) in 64 countries. Methods: This 24-week, multicenter, randomized, double-blind, placebo-controlled study evaluated the efficacy, safety and ...
Yu Nakamura, Yukimichi Imai, Masahiro Shigeta, Ana Graf, Toru Shirahase, Hyosung Kim, Akifumi Fujii, Joji Mori, Akira Homma   +8 more
doaj   +1 more source

Characteristics of patients with Alzheimer’s disease who switch to rivastigmine transdermal patches in routine clinical practice

Patient Preference and Adherence, 2013
Secundino López-Pousa,1 Francisco Javier Arranz21Unit for Assessment of Memory and Dementia, Institut d’Assistència Sanitària de Girona, Salt, Girona, 2CNS Area, Medical Department and Health Innovation, Esteve,
López-Pousa S, Arranz FJ
doaj  

Tramiprosate, the Active Agent of ALZ‐801, Modulates Amyloidogenic APP Processing and Tau Phosphorylation in a Cellular Model of Alzheimer's Disease

Drug Development Research, Volume 87, Issue 4, June 2026.
ABSTRACT ALZ‐801, a valine‐conjugated prodrug of tramiprosate, has recently been evaluated in a Phase III trial as a potential Alzheimer's disease (AD)‐modifying therapy. Tramiprosate reduces misfolding of amyloid beta (Aβ) monomers and inhibits oligomer formation. In the present study, we investigated tramiprosate's effects on amyloidogenic processing
Kevser Biberoglu, Ozden Tacal
wiley   +1 more source

Rivastigmine for dementia associated with Parkinson's disease

, 2004
Background: Cholinergic deficits are prominent in patients who have dementia associated with Parkinson's disease. We investigated the effects of the dual cholinesterase inhibitor rivastigmine in such patients.
De Deyn, PP, Albanese, A, Byrne, E.J., Albanese, A., Aarsland, D, Lane, R, De Deyn, P.P., Poewe, W., Lees, A, Robillard, A., Emre, M., Byrne, EJ, Tekin, S., Durif, F, Malet, R.M., Wolters, E., Rosa, MM, Wolters, E, Durif, F., Robillard, A, Kulisevsky, J, Tekin, S, Poewe, W, van Laar, T, van Laar, T., Deuschl, G., Rosa, M.M., Aarsland, D., Quarg, P., Albanese, Alberto, Lane, R., Malet, Rosa Mar\ueda, Wolters, Erik, Kulisevsky, J., Deuschl, G, De Deyn, Peter Paul, Lees, A., Lees, Alan, Emre, M, Quarg, P   +39 more
core   +1 more source

Recent Progress on Enzyme Immobilization: Materials, Strategies, and Applications

Food Bioengineering, Volume 5, Issue 2, Page 220-243, June 2026.
Enzyme immobilization technology has undergone substantial evolution driven by advances in materials science. This review systematically examines the recent advances in enzyme immobilization since 2024, with a focused analysis of five major categories of enzyme carriers including covalent organic framework, metal‐organic frameworks, polymers, carbon ...
Shuran Wang, Ruoke Li, Yixuan Xie, Hanya Zhang, Xiaoyu Huang, Siwei Chen, Weixin Xu, Yueling Liu   +7 more
wiley   +1 more source

Rivastigmine does not alter APP holoprotein.

, 2013
APP levels in lysates of cerebrocortical cultures treated with vehicle or rivastigmine were measured by Western blot using the 22C11 antibody. No difference in APP holoprotein was found in either the 5 µM or 10 µM rivastigmine treatments, indicating that
Jason A. Bailey (229720), Debomoy K. Lahiri (331483), Balmiki Ray (331481), Nigel H. Greig (214075)   +3 more
core   +1 more source

Effects of rivastigmine on gait in patients with neurodegenerative disorders: A systematic review and meta-analysis.

PLoS ONE
Background & aimsGait disturbances are commonly observed in patients with neurodegenerative disorders, including Alzheimer's disease, Parkinson's disease, and higher-level gait disorders, which are associated with cholinergic deficits.
Sung Ryul Shim, Jong-Yeup Kim, Kyum-Yil Kwon, Jieun Shin, Yungjin Lee, Seon-Min Lee   +5 more
doaj   +1 more source

Rivastigmine in the treatment of Alzheimer's disease: an update

, 2007
Maria Luisa Onor, Marianna Trevisiol, Eugenio AgugliaDepartment of Clinical, Morphological and Technological Sciences, U.C.O. of Clinical Psychiatry, University of Trieste, Trieste, ItalyAbstract: Alzheimer’s disease is the most common form of ...
Marianna Trevisiol, Maria Luisa Onor, Eugenio Aguglia   +2 more
core  

EFFECTS OF 6-MONTHS TREATMENT WITH DONEPEZIL AND RIVASTIGMIN ON RESULTS OF NEUROPSYCHOLOGICAL TESTS OF MMSE, NPI, CLOCK AND BENDER IN PATIENTS WITH ALZHEIMER'S DISEASE

Acta Medica Iranica, 2008
Alzheimer's disease is the most common degenerative disease of brain. Nowadays, the most common treatment being used to slow down disease progression, include Donepezil , Rivastigmine and Galantamine, which all of them act as inhibitors of acetyl ...
R. Abolfazli, S. Ghazanshahi M. Nazeman   +1 more
doaj  

The Role of Magnetic Resonance Spectroscopy (MRS), Diffusion‐Tensor‐Imaging (DTI) and Structural MRI in the Alzheimer's Disease and Mild Cognitive Impairment Diagnosis: A Review

Journal of Magnetic Resonance Imaging, Volume 63, Issue 6, Page 1509-1545, June 2026.
ABSTRACT Alzheimer's disease (AD) is one of the most common neurological disorders affecting older adults, with approximately 7.2 million cases only in the United States. This number is projected to increase to 13.8 million in the United States by 2060, leading to increased expenditures for healthcare, long‐term care and hospice services. Consequently,
Valentina Zecca, Gianmauro Palombelli, Nicola Vanacore, Rossella Canese   +3 more
wiley   +1 more source